available for iOS, Android and web
May 31, 2011
A ban on direct-to-consumer advertising (DTCA) of new medicines during the first two years after regulatory approval could prove harmful to patients, the US Congressional Budget Office (CBO) has warned.
December 06, 2010
Documents released ahead of a US meeting on Tuesday suggest the chances of Orexigen's Contrave becoming the first weight loss drug to be approved in the USA in over a decade are not so good
October 18, 2010
Johnson & Johnson has been told to pay $257.7 million by a jury in Louisiana for claiming that its antipsychotic Risperdal was superior to similar drugs and downplaying its link to diabetes
PharmaTimes 2014 Copyright | RSS Feed Subscriptions